このエントリーをはてなブックマークに追加
ID 34232
フルテキストURL
著者
Matsuura, Hiroko Department of Medicine and Medical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Murakami, Takashi Department of Cardiology, Cardiovascular Center, Sakakibara Hospital
Hina, Kazuyoshi Department of Cardiology, Cardiovascular Center, Sakakibara Hospital
Yamamoto, Keizo Department of Cardiology, Cardiovascular Center, Sakakibara Hospital
Kawamura, Hiroshi Department of Cardiology, Cardiovascular Center, Sakakibara Hospital
Sogo, Taiji Department of Cardiovascular Medicine, Takamatsu Red Cross Hospital
Shinohata, Ryoko Department of Medical Technology, Okayama University Graduate School of Health Sciences
Usui, Shinichi Department of Medical Technology, Okayama University Graduate School of Health Sciences
Ninomiya, Yoshifumi Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kusachi, Shozo Department of Medical Technology, Okayama University Graduate School of Health Sciences
抄録

Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients.
Methods: Patients (n=97) were classified into chronic AF (CAF; n=14), paroxysmal AF (PAF; n=18) and normal sinus rhythm (NSR; n=65) groups. The plasma BNP values were analyzed with logarithmic transformation.
Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; -1 SD and +1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p<0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p<0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level.
Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.

キーワード
clinical study
cardiomyopathy
tachyarrhythmia
enzyme immunoassay
peptide
sensitivity and specificity
備考
Published with permission from the copyright holder.
This is a author's copy,as published in Clinical Biochemistry , 2008 Vol.41 Issue.3 pp.134-139
Publisher URL: http://dx.doi.org/10.1016/j.clinbiochem.2007.10.015
Direct access to Thomson Web of Science record
Copyright © The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
発行日
2008-02
出版物タイトル
Clinical Biochemistry
41巻
3号
出版者
Elsevier Inc.
開始ページ
134
終了ページ
139
ISSN
0009-9120
NCID
AA00607603
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Sience KeyUT
Submission Path
biochemistry/12